Mirum Pharmaceuticals Receives the US FDA Approval for Ctexli to Treat Cerebrotendinous Xanthomatosis
Shots:
- The US FDA has approved Ctexli (chenodiol) to treat cerebrotendinous xanthomatosis (CTX) in adults
- Efficacy was established in crossover withdrawal P-III (RESTORE) trial assessing Ctexli (250mg, PO, TID) vs PBO in pts for 24wks.
- Study showed reduced levels of plasma cholestanol & urine 23S-pentol in pts compared to PBO
Ref: Prnewswire | Image: Mirum
Related News:- Mirum Pharmaceuticals’ Livmarli Receives the EC’s Approval to Treat Progressive Familial Intrahepatic Cholestasis (PFIC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
